MHR
SMMT icon

Matthew Hamilton Rosenberg’s Summit Therapeutics SMMT Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.3K Hold
501
– – ﹤0.01% 663
2026
Q1 		$9.5K Hold
501
– – ﹤0.01% 619
2025
Q4 		$8.76K Hold
501
– – ﹤0.01% 645
2025
Q3 		$10.4K Hold
501
– – ﹤0.01% 627
2025
Q2 		$10.7K Buy
+501
New +$11.4K ﹤0.01% 645

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Matthew Hamilton Rosenberg's SMMT Position: Q2 2026 in Review

Matthew Hamilton Rosenberg held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 501 shares worth $7.3K. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Matthew Hamilton Rosenberg first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.7K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Matthew Hamilton Rosenberg held 501 shares of Summit Therapeutics worth $7.3K as of Q2 2026.
  • Matthew Hamilton Rosenberg left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Matthew Hamilton Rosenberg's portfolio in Q2 2026, its #663 holding.
  • Matthew Hamilton Rosenberg first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Matthew Hamilton Rosenberg's Summit Therapeutics position peaked at $10.7K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Matthew Hamilton Rosenberg's 13F filing for Q2 2026, filed 17 Jul 2026.